Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO® 2Q 2026 net product sales of $2.3 million AUVELITY launched for treatment of agitation associated […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Nexus Industrial REIT Announces Second Quarter 2026 Financial Results financialpost.com
